ArticleNeuropsychopharmacology reports2019
Brexpiprazole has a low risk of dopamine D
Article in Neuropsychopharmacology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Brexpiprazole for the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease: Clinical Perspectives.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026Review
- Dopamine DPsychological medicine · 2025Article
- Risk of relapse during tapering of antipsychotic medication after a first psychotic episode: association with D2 receptor affinity but not with tapering speed.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2025Article
- Electroconvulsive therapy for depression and oral dyskinesia in a patient who developed parkinsonism induced by valbenazine.PCN reports : psychiatry and clinical neurosciences · 2025Article
- Brexpiprazole: A new option in treating agitation in Alzheimer's dementia-Insights from transgenic mouse models.Neuropsychopharmacology reports · 2024Article
- Brexpiprazole Attenuates Aggression, Suicidality and Substance Use in Borderline Personality Disorder: A Case Series.Medicina (Kaunas, Lithuania) · 2024Article
- Synergistic anti-depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice.Neuropsychopharmacology reports · 2023Article
- Spontaneous head twitches in aged rats: behavioral and molecular study.Psychopharmacology · 2022Article
- Discovery research and development history of the dopamine DNeuropsychopharmacology reports · 2021Review
- Review
- Treatment-resistant schizophrenia characterised by dopamine supersensitivity psychosis and efficacy of asenapine.BMJ case reports · 2021Article
- Effect of Switching to Brexpiprazole on Plasma Homovanillic Acid Levels and Antipsychotic-Related Side Effects in Patients with Schizophrenia or Schizoaffective Disorder.Neuropsychiatric disease and treatment · 2021Article
- Brexpiprazole for the Treatment of Schizophrenia in Adults: An Overview of Its Clinical Efficacy and Safety and a Psychiatrist's Perspective.Drug design, development and therapy · 2020Review
- Brexpiprazole has a low risk of dopamine DNeuropsychopharmacology reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLong-term antipsychotic treatment in patients with schizophrenia can induce supersensitivity psychosis and tardive dyskinesia which is thought to be caused by dopamine D
methodsThe maximum D
resultsHaloperidol and brexpiprazole (30 mg/kg: approximately tenfold ED
conclusionBrexpiprazole has a low risk of D
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.